- Home
- FT vs SCPH Comparison
FT vs SCPH Comparison
Compare FT & SCPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FT
- SCPH
- Stock Information
- Founded
- FT 1988
- SCPH 2013
- Country
- FT United States
- SCPH United States
- Employees
- FT N/A
- SCPH N/A
- Industry
- FT Trusts Except Educational Religious and Charitable
- SCPH Biotechnology: Pharmaceutical Preparations
- Sector
- FT Finance
- SCPH Health Care
- Exchange
- FT Nasdaq
- SCPH Nasdaq
- Market Cap
- FT 185.7M
- SCPH 179.6M
- IPO Year
- FT N/A
- SCPH 2017
- Fundamental
- Price
- FT $7.29
- SCPH $3.38
- Analyst Decision
- FT
- SCPH Strong Buy
- Analyst Count
- FT 0
- SCPH 2
- Target Price
- FT N/A
- SCPH $15.00
- AVG Volume (30 Days)
- FT 63.0K
- SCPH 442.5K
- Earning Date
- FT 01-01-0001
- SCPH 11-13-2024
- Dividend Yield
- FT 7.85%
- SCPH N/A
- EPS Growth
- FT N/A
- SCPH N/A
- EPS
- FT N/A
- SCPH N/A
- Revenue
- FT N/A
- SCPH $30,278,000.00
- Revenue This Year
- FT N/A
- SCPH $172.64
- Revenue Next Year
- FT N/A
- SCPH $131.43
- P/E Ratio
- FT N/A
- SCPH N/A
- Revenue Growth
- FT N/A
- SCPH 303.87
- 52 Week Low
- FT $5.97
- SCPH $3.08
- 52 Week High
- FT $7.23
- SCPH $6.54
- Technical
- Relative Strength Index (RSI)
- FT 40.30
- SCPH 44.62
- Support Level
- FT $7.19
- SCPH $3.27
- Resistance Level
- FT $7.35
- SCPH $3.58
- Average True Range (ATR)
- FT 0.09
- SCPH 0.19
- MACD
- FT 0.00
- SCPH 0.01
- Stochastic Oscillator
- FT 43.75
- SCPH 22.92
About FT Franklin Universal Trust
Franklin Universal Trust is a closed-end management investment company. Its primary investment objective is to provide high, current income consistent with the preservation of capital. Its secondary objective is the growth of income through dividend increases and capital appreciation. The fund invests in two asset classes being the high yield bonds and utility stocks.
About SCPH scPharmaceuticals Inc.
scPharmaceuticals Inc is a pharmaceutical company focused on developing and commercializing products that have the potential to optimize the delivery of infused therapies, advance patient care and reduce healthcare costs. The company's main product is Furoscix. Furoscix consists of this patented formulation of furosemide for subcutaneous administration with wearable, portable sc2Wear Infusor for the treatment of edema in patients with heart failure.